The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 06, 2020
Filed:
Mar. 04, 2019
Applicant:
International Aids Vaccine Initiative, New York, NY (US);
Inventors:
Christopher L. Parks, New York, NY (US);
Maoli Yuan, New York, NY (US);
Xinsheng Zhang, New York, NY (US);
Aaron Wilson, New York, NY (US);
Angela Grazia Lombardo, New York, NY (US);
Eddy Sayeed, New York, NY (US);
Josephine Helena Cox, New York, NY (US);
Takashi Hironaka, Ibaraki, JP;
Makoto Inoue, Ibaraki, JP;
Hiroto Hara, Ibaraki, JP;
Assignee:
INTERNATIONAL AIDS VACCINE INITIATIVE, New York, NY (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 39/21 (2006.01); A61K 39/00 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/57 (2013.01); A61K 2039/575 (2013.01); A61K 2039/70 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16234 (2013.01); C12N 2740/16271 (2013.01); C12N 2740/16334 (2013.01); C12N 2760/18443 (2013.01); C12N 2760/18843 (2013.01); C12N 2760/18871 (2013.01); C12N 2760/20243 (2013.01);
Abstract
The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.